Different molecular targets, one purpose – treatment of depression

1. World Health Organization. World Mental Health Day DEPRESSION: A Global Crisis. 2012. Search in Google Scholar

2. Donohue MR, Luby J. Depression. The Curated Reference Collection in Neuroscience and Biobehavioral Psychology. Elsevier Science Ltd. 2016:366–73. Search in Google Scholar

3. Smith K. Mental health: a world of depression. Natur. 2014;515:181.10.1038/515180a Search in Google Scholar

4. Hagen EH. Evolutionary theories of depression: A critical review. Can J Psychiatry. 2011;56:716–26.10.1177/070674371105601203 Search in Google Scholar

5. Peng G, Tian J, Gao X, Zhou Y, Qin X. Research on the pathological mechanism and drug treatment mechanism of depression. Curr Neuropharmacol. 2015;13(4):514–23.10.2174/1570159X1304150831120428 Search in Google Scholar

6. Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: Leads for future research and new drug developments in depression. Metab Brain Dis. 2009;24:27–53.10.1007/s11011-008-9118-1 Search in Google Scholar

7. Evans DL, Charney DS, Lewis L, Golden RN, Gorman JM, Krishnan KRR, et al. Mood disorders in the medically ill: Scientific review and recommendations. Biol Psychiatry. 2005;58:175–89.10.1016/j.biopsych.2005.05.001 Search in Google Scholar

8. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999;38(8):1083–152.10.1016/S0028-3908(99)00010-6 Search in Google Scholar

9. Berger M, Gray JA, Roth BL. The Expanded Biology of Serotonin. Annu Rev Med. 2009;60(1):355–66.10.1146/annurev.med.60.042307.110802586429319630576 Search in Google Scholar

10. Goluch-Koniuszy Z, Fugiel J. Rola składników diety w syntezie wybranych neurotransmiterów. KOSMOS. 2016;65(4):523–34. Search in Google Scholar

11. Kazula A. Mechanizmy działania selektywnych inhibitorów wychwytu zwrotnego serotoniny (SSRI) w depresji. Farm Pol. 2014; 70(12):711–24. Search in Google Scholar

12. Nutt DJ, Baldwin DS, Clayton AH, Elgie R, Lecrubier Y, Montejo AL, et al. The role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry. 2006;67: 46–9. Search in Google Scholar

13. Aggarwal S, Mortensen O V. Overview of monoamine transporters. Curr Protoc Pharmacol. 2017;79:12.16.1–12.16.17.10.1002/cpph.32584147329261228 Search in Google Scholar

14. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007;151(6):737–48.10.1038/sj.bjp.0707253201412017471183 Search in Google Scholar

15. Strawn JR, Geracioti L, Rajdev N, Clemenza K, Levine A. Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. Expert Opin Pharmacother. 2018;19(10):1057–70.10.1080/14656566.2018.1491966634039530056792 Search in Google Scholar

16. Blier P, El-Mansari M. Serotonin and beyond: Therapeutics for major depression. Philos Trans R Soc Lond B Biol Sci. 2013;368(1615): 20120536.10.1098/rstb.2012.0536 Search in Google Scholar

17. Jeleń A, Sałagacka A, Ballcerczak E. Charakterystyka wybranych mechanizmów molekularnych wpływających na farmakokinetykę i farmakodynamikę leków przeciwdepresyjnych. Postep Hig Med Dosw. 2015;69:753–62.10.5604/17322693.1160610 Search in Google Scholar

18. De Monte C, D’Ascenzio M, Guglielmi P, Mancini V, Carradori S. Opening New Scenarios for Human MAO Inhibitors. Cent Nerv Syst Agents Med Chem. 2016;16(2):98–104.10.2174/1871524915666150831141705 Search in Google Scholar

19. Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Revi Neurosci. 2006;7(4):295–309.10.1038/nrn1883 Search in Google Scholar

20. Carradori S, Petzer JP. Novel monoamine oxidase inhibitors: A patent review. Expert Opin Ther Pat. 2015;25(1):91–110.10.1517/13543776.2014.982535 Search in Google Scholar

21. Jarema M, Dudek D, Landowski J, Heitzman J, Rabe-Jabłońska J, Rybakowski J. Trazodon-lek przeciwdepresyjny: mechanizm działania i miejsce w leczeniu depresji. Psychiatr Pol. 2011;45(4): 611–25. Search in Google Scholar

22. Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord. 1998;51(3):237–54.10.1016/S0165-0327(98)00222-5 Search in Google Scholar

23. DeVane CL, Grothe DR, Smith SL. Pharmacology of antidepressants: focus on nefazodone. J Clin Psychiatry. 2002;63(1):10–7. Search in Google Scholar

24. Basgioura k i E, Papazisis G, Apostolidis A, Goulas A. Pharmacodynamic and pharmacokinetic properties of the novel antidepressant vortioxetine. Aristotle Univ Med J. 2016;43(3). Search in Google Scholar

25. Wang S-M, Han C, Lee S-J, Patkar AA, Masand PS, Pae C-U. Vilazodone for the Treatment of Depression: An Update. Chonnam Med J. 2016;52(2):91.10.4068/cmj.2016.52.2.91488058427231672 Search in Google Scholar

26. Wysokiński A, Kłoszewska I. Wilazodon – nowy wielofunkcyjny lek przeciwdepresyjny. Psychiatria. 2013;10(2):72–5. Search in Google Scholar

27. Croom KF, Perry CM, Plosker GL. Mirtazapine: A review of its use in major depression and other psychiatric disorders. CNS Drug. 2009;23(5):427–52.10.2165/00023210-200923050-0000619453203 Search in Google Scholar

28. Zupancic M, Guilleminault C. Agomelatine: A preliminary review of a new antidepressant. CNS Drugs. 2006;20(12):981–92.10.2165/00023210-200620120-0000317140278 Search in Google Scholar

29. Anttila S, Leinonen E. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001;7(3):249–64.10.1111/j.1527-3458.2001.tb00198.x649414111607047 Search in Google Scholar

30. Brogden R, Heel R, Speight T, Avery G. Mianserin: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs. 1978;16(4):273–301.10.2165/00003495-197816040-00001359311 Search in Google Scholar

31. Quera-Salva M-A, Lemoine P, Guilleminault C. Impact of the novel antidepressant agomelatine on disturbed sleep–wake cycles in depressed patients. Hum Psychopharmacol Clin Exp. 2010;25(3):222–9.10.1002/hup.111220373473 Search in Google Scholar

32. Prymus A, Krzystanek M, Bednarska-Półtorak K, Krupka-Matuszczyk I. Agomelatine – new possibility in treatment of affective disorders and sleep disorders. Probl Med Rodz. 2009;11(1). Search in Google Scholar

33. Roberts RJ, Lohano KK, El-Mallakh RS. Antipsychotics as antidepressants. Asia Pac Psychiatry. 2016;8(3):179–88.10.1111/appy.1218625963405 Search in Google Scholar

34. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry. 1999;60(4):256–9.10.4088/JCP.v60n0410 Search in Google Scholar

35. Meltzer HY. Update on typical and atypical antipsychotic drugs. Annu Rev Med. 2013;64(1):393–406.10.1146/annurev-med-050911-16150423020880 Search in Google Scholar

36. Suttajit S, Srisurapanont M, Maneeton N, Maneeton B. Quetiapine for acute bipolar depression: A systematic review and meta-analysis. Drug Des Devel Ther. 2014;8:827–38.10.2147/DDDT.S63779407739025028535 Search in Google Scholar

37. Wasik A, Koałczkowski M, Wesoołwska A. Lurasidon - Nowy atypowy neuroleptyk o właściwościach przeciwdepresyjnych. Psychiatria. 2014;11(1):1–8. Search in Google Scholar

38. Permoda-Osip A, Rybakowski J. Koncepcja glutaminergiczna chorób afektywnych. Glutamatergic conception of mood disorders. Psychiatr Pol. 2011;45(6):875–88. Search in Google Scholar

39. Tokarski K, Kusek M, Sowa J, Bobula B. Receptory 5-HT7 a patofizjologia chorób afektywnych i działanie leków przeciwdepresyjnych. Postepy Hig Med Dosw. 2014;68:1104–13.10.5604/17322693.112092925228519 Search in Google Scholar

40. Dziugieł R. Ketamina w walce z depresją, czyli stary anestetyk w nowej odsłonie. Probl Nauk Med i Nauk o Zdrowiu. 2019;10:25–32. Search in Google Scholar

41. Tibensky BN, de Léséleuc L, Perras C, Picheca L. Esketamine for Treatment-Resistant Depression. CADTH Issues in Emerging Health Technologies. 2016;176 Search in Google Scholar

42. Kaur U, Pathak BK, Singh A, Chakrabarti SS. Esketamine: a glimmer of hope in treatment-resistant depression. Eur Arch Psychiatry Clin Neurosci. 201910.1007/s00406-019-01084-z31745646 Search in Google Scholar

43. Palazidou E. The neurobiology of depression. Br Med Bull. 2012; 101:127–4510.1093/bmb/lds00422334281 Search in Google Scholar

44. Wagstaff AJ, Ormrod D, Spencer CM. Tianeptine: A review of its use in depressive disorders. CNS Drug. 2001;15(3):231–59.10.2165/00023210-200115030-0000611463130 Search in Google Scholar

45. Brink CB, Harvey BH, Brand L. Tianeptine: a novel atypical antidepressant that may provide new insights into the biomolecular basis of depression. Recent pat CNS Drug Discov. 2006;1:29–41.10.2174/15748890677524532718221189 Search in Google Scholar

46. Alamo C, García-Garcia P, Lopez-Muñoz F, Zaragozá C. Tianeptine, an atypical pharmacological approach to depression. Rev Psiquiatr y Salud Ment. 2019;12(3):170–86.10.1016/j.rpsm.2018.09.00230612921 Search in Google Scholar

47. McEwen BS, Chattarji S, Diamond DM, Jay TM, Reagan LP, Svenningsson P, et al. The neurobiological properties of tianeptine (Stablon): From monoamine hypothesis to glutamatergic modulation. Mol Psychiatr. 2010;15(3):237–49.10.1038/mp.2009.80290220019704408 Search in Google Scholar

48. Madison CA, Eitan S. Buprenorphine: Prospective novel therapy for depression and PTSD. Psychol Med. 2020;50(6):881–93.10.1017/S003329172000052532204739 Search in Google Scholar

49. Lutz PE, Kieffer BL. Opioid receptors: Distinct roles in mood disorders. TINS. 2013;36(3):195–206. Search in Google Scholar

50. Bodkin JA, Zornberg GL, Lukas SE, Cole JO. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995;15(1):49–57.10.1097/00004714-199502000-000087714228 Search in Google Scholar

51. Karp J, Butters M, Begley A, Miller M, Lenze E, Blumberger D, et al. Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. J Clin Psychiatry. 2014;75(8):e785–93.10.4088/JCP.13m08725415731725191915 Search in Google Scholar

52. Yovell Y, Bar G, Mashiah M, Baruch Y, Briskman I, Asherov J, et al. Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: A randomized controlled trial. Am J Psychiatry. 2016;173(5):491–8.10.1176/appi.ajp.2015.1504053526684923 Search in Google Scholar

53. Stoll A, Rueter S. Treatment augmentation with opiates in severe and refractory major depression. Am J Psychiatr. 1999;156(12):2017. Search in Google Scholar

54. Serafini G, Adavastro G, Canepa G, De Berardis D, Valchera A, Pompili M, et al. The efficacy of buprenorphine in major depression, treatment-resistant depression and suicidal behavior: A systematic review. Int J Mol Sci. 2018:19(8).10.3390/ijms19082410612150330111745 Search in Google Scholar

55. Toll L, Bruchas MR, Calo’ G, Cox BM, Zaveri NT. Nociceptin/orphanin FQ receptor structure, signaling, ligands, functions, and interactions with opioid systems. Pharmacol Rev. 2016;68(2):419–57.10.1124/pr.114.009209481342726956246 Search in Google Scholar

56. Rorick-Kehn LM, Witkin JM, Statnick MA, Eberle EL, McKinzie JH, Kahl SD, et al. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacol. 2014;77:131–44.10.1016/j.neuropharm.2013.09.02124071566 Search in Google Scholar

57. Broom DC, Jutkiewicz EM, Folk JE, Traynor JR, Rice KC, Woods JH. Convulsant activity of a non-peptidic δ-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats. Psychopharmacol. 2002;164(1):42–8.10.1007/s00213-002-1179-y Search in Google Scholar

58. Broom DC, Jutkiewicz EM, Folk JE, Traynor JR, Rice KC, Woods JH. Nonpeptidic δ-opioid receptor agonists reduce immobility in the forced swim assay in rats. Neuropsychopharmacol. 2002;26(6):744–55.10.1016/S0893-133X(01)00413-4 Search in Google Scholar

59. Dripps IJ, Jutkiewicz EM. Delta opioid receptors and modulation of mood and emotion. Handb Exp Pharmacol. 2018;247:179–97. Search in Google Scholar

60. Crippa JA, Guimarães FS, Campos AC, Zuardi AW. Translational investigation of the therapeutic potential of cannabidiol (CBD): Toward a new age. Front Immunol. 2018;9:2009.10.3389/fimmu.2018.02009616164430298064 Search in Google Scholar

61. Schier A, Ribeiro N, Coutinho D, Machado S, Arias-Carrion O, Crippa J, et al. Antidepressant-like and anxiolytic-like effects of cannabidiol: A chemical compound of cannabis sativa. CNS Neurol Disord Drug Targets. 2014;13(6):953–60.10.2174/187152731366614061211483824923339 Search in Google Scholar

62. Dulava SC, Janowsky DS. Cholinergic regulation of mood: From basic and clinical studies to emerging therapeutics. Mol Psychiatry. 2019;24(5):694–709.10.1038/s41380-018-0219-x719231530120418 Search in Google Scholar

63. Adzic M, Brkic Z, Mitic M, Francija E, Jovicic MJ, Radulovic J, et al. Therapeutic strategies for treatment of inflammation-related depression. Curr Neuropharmacol. 2018;16(2):176–209.10.2174/1570159X15666170828163048588337928847294 Search in Google Scholar

64. World Health Organization. Depression and Other Common Mental Disorders: Global Health Estimates. Geneva; 2017. Search in Google Scholar

65. Ionescu DF, Papakostas GI. Experimental medication treatment approaches for depression. Transl Psychiatry. 2017;7(3):e1068.10.1038/tp.2017.33541667628323287 Search in Google Scholar

66. Won E, Kang J, Choi S, Kim A, Han KM, Yoon HK, et al. The association between substance P and white matter integrity in medication-naive patients with major depressive disorder. Sci Rep. 2017;7:9707.10.1038/s41598-017-10100-y557535028852030 Search in Google Scholar